| Stereochemistry | ACHIRAL |
| Molecular Formula | C10H13ClN2S |
| Molecular Weight | 228.742 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
ClC1=CC=CC(SC2CCNCC2)=N1
InChI
InChIKey=GGALEXMXDMUMDM-UHFFFAOYSA-N
InChI=1S/C10H13ClN2S/c11-9-2-1-3-10(13-9)14-8-4-6-12-7-5-8/h1-3,8,12H,4-7H2
| Molecular Formula | C10H13ClN2S |
| Molecular Weight | 228.742 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Anpirtoline [D 16949] is a dichloropyridine derivative with antinociceptive and antidepressant activity. Anpirtoline has been described as an agonist at 5-HT1B and 5-HT1D receptors with a relatively high potency. It also acts as an agonist at 5-HT1A receptors, but has a lower potency than at the 5-HT1B sites. In addition, Anpirtoline acts as an antagonist at 5-HT3 receptors. The drug was in phase I clinical trials with ASTA Medica in Germany for the treatment of pain and depression, but development was suspended.
CNS Activity
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
| 7.53 null [pKi] |
PubMed
Sample Use Guides
The pain relieving properties of imipramine (100 mg orally), tramadol (150 mg orally), and anpirtoline (60 mg orally) were compared in 16 healthy subjects in a cross-over, double-blind, randomized, and placebo-controlled study.
Route of Administration:
Oral
